Literature DB >> 18386774

Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Pedro P Medina1, Octavio A Romero, Takashi Kohno, Luis M Montuenga, Ruben Pio, Jun Yokota, Montse Sanchez-Cespedes.   

Abstract

Components of the SWI/SNF chromatin-remodeling complex, such as INI1, are inactivated in human cancer and, thus, act as tumor suppressors. Here we screened for mutations the entire coding sequence of BRG1 (SMARCA4), which encodes the ATPase of the complex, in 59 lung cancer cell lines of the most common histopathological types. Mutations were detected in 24% of the cancer cell lines, many of them in cells commonly used for lung cancer research. All mutations were homozygous and most predicted truncated proteins. The alterations were significantly more frequent in the non-small-cell lung cancer (NSCLC) type (13/37, 35%) as compared to the small-cell lung cancer (SCLC) type (1/19, 5%) (P<0.05; Fisher's Exact test) and BRG1 was the fourth most frequently altered gene in NSCLC cell lines. BRG1 mutations coexisted with mutations/deletions at KRAS, LKB1, NRAS, P16, and P53. However, alterations at BRG1 always occurred in the absence of MYC amplification, suggesting a common role in lung cancer development. In conclusion, our data strongly support that BRG1 is a bona fide tumor suppressor and a major factor in lung tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18386774     DOI: 10.1002/humu.20730

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  126 in total

Review 1.  The role of LKB1 in lung cancer.

Authors:  Montse Sanchez-Cespedes
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

Review 2.  Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins.

Authors:  Alea A Mills
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

3.  Modeling gene-wise dependencies improves the identification of drug response biomarkers in cancer studies.

Authors:  Olga Nikolova; Russell Moser; Christopher Kemp; Mehmet Gönen; Adam A Margolin
Journal:  Bioinformatics       Date:  2017-05-01       Impact factor: 6.937

4.  PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion.

Authors:  Ester Bonastre; Sara Verdura; Ilse Zondervan; Federica Facchinetti; Sylvie Lantuejoul; Maria Dolores Chiara; Juan Pablo Rodrigo; Julian Carretero; Enric Condom; Agustin Vidal; David Sidransky; Alberto Villanueva; Luca Roz; Elisabeth Brambilla; Suvi Savola; Montse Sanchez-Cespedes
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

Review 5.  Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?

Authors:  Adi F Gazdar; Boning Gao; John D Minna
Journal:  Lung Cancer       Date:  2010-01-15       Impact factor: 5.705

6.  Epigenetic dysregulation in cancer.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

7.  Mutations in ACTRT1 and its enhancer RNA elements lead to aberrant activation of Hedgehog signaling in inherited and sporadic basal cell carcinomas.

Authors:  Elodie Bal; Hyun-Sook Park; Zakia Belaid-Choucair; Hülya Kayserili; Magali Naville; Marine Madrange; Elena Chiticariu; Smail Hadj-Rabia; Nicolas Cagnard; Francois Kuonen; Daniel Bachmann; Marcel Huber; Cindy Le Gall; Francine Côté; Sylvain Hanein; Rasim Özgür Rosti; Ayca Dilruba Aslanger; Quinten Waisfisz; Christine Bodemer; Olivier Hermine; Fanny Morice-Picard; Bruno Labeille; Frédéric Caux; Juliette Mazereeuw-Hautier; Nicole Philip; Nicolas Levy; Alain Taieb; Marie-Françoise Avril; Denis J Headon; Gabor Gyapay; Thierry Magnaldo; Sylvie Fraitag; Hugues Roest Crollius; Pierre Vabres; Daniel Hohl; Arnold Munnich; Asma Smahi
Journal:  Nat Med       Date:  2017-09-04       Impact factor: 53.440

8.  Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.

Authors:  Gregory R Hoffman; Rami Rahal; Frank Buxton; Kay Xiang; Gregory McAllister; Elizabeth Frias; Linda Bagdasarian; Janina Huber; Alicia Lindeman; Dongshu Chen; Rodrigo Romero; Nadire Ramadan; Tanushree Phadke; Kristy Haas; Mariela Jaskelioff; Boris G Wilson; Matthew J Meyer; Veronica Saenz-Vash; Huili Zhai; Vic E Myer; Jeffery A Porter; Nicholas Keen; Margaret E McLaughlin; Craig Mickanin; Charles W M Roberts; Frank Stegmeier; Zainab Jagani
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

9.  Possible involvement of LKB1-AMPK signaling in non-homologous end joining.

Authors:  A Ui; H Ogiwara; S Nakajima; S Kanno; R Watanabe; M Harata; H Okayama; C C Harris; J Yokota; A Yasui; T Kohno
Journal:  Oncogene       Date:  2013-04-15       Impact factor: 9.867

Review 10.  A rationale to target the SWI/SNF complex for cancer therapy.

Authors:  Anja F Hohmann; Christopher R Vakoc
Journal:  Trends Genet       Date:  2014-06-03       Impact factor: 11.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.